The October 1, 2018, article by Janjigian et al, entitled “CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer” (J Clin Oncol 10.1200/JCO.2017.76.6212), was published with errors in the AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.
Emiliano Calvo’s COIs were given as:
Emiliano Calvo
Consulting or Advisory Role: Novartis, GlaxoSmithKline, Astellas Pharma, Roche/Genentech, Eli Lilly/ImClone, Nanobiotix, Pfizer
Speakers' Bureau: Novartis
Research Funding: Boehringer Ingelheim, Roche/Genentech, Bristol-Myers Squibb, Novartis, PsiOxus Therapeutics, Janssen Oncology, Eisai, AbbVie, OncoMed, PharmaMar, Puma Biotechnology, Spectrum Pharmaceuticals, Sanofi, Eli Lilly, Pfizer, Merck, Nektar, Millennium
Travel, Accommodations, Expenses: Eli Lilly, PsiOxus Therapeutics, Novartis
Other Relationship: Pierre Fabre
They should have been given as:
Emiliano Calvo
Employment: START, HM Hospitales Group
Leadership: START
Stock and Other Ownership Interests: START, Oncoart Associated, International Cancer Consultants
Honoraria: HM Hospitales Group
Consulting or Advisory Role: Novartis, Janssen-Cilag, PsiOxus Therapeutics, Seattle Genetics, EUSA Pharma, AbbVie, Celgene, AstraZeneca, Guidepoint Global, GLG, SERVIER, Amcure Roche/Genentech, Nanobiotix, Pfizer
Speakers' Bureau: Novartis
Research Funding: Novartis, AstraZeneca, BeiGene, START
Travel, Accommodations, Expenses: Roche/Genentech
Other Relationship: President and Founder of Foundation INTHEOS (Investigational Therapeutics in Oncological Sciences)
This has been corrected as of January 11, 2019. The author apologizes for the errors.